Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.47 |
| ▸ | GZMB | P10144 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP4 | P49662 | 1/20 | 0.42 |
| ▸ | CASP5 | P51878 | 1/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.42 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23132679 | 1.00 | TASP1 (0.52) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL2381289 | 1.00 | TASP1 (0.52) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL23924919 | 1.00 | TASP1 (0.52) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL23133165 | 1.00 | TASP1 (0.52) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL5746872 | 0.93 | TASP1 (0.61) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL20257260 | 0.93 | TASP1 (0.53) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL20257263 | 0.93 | TASP1 (0.53) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL15485396 | 0.88 | TASP1 (0.49) | TASP1ENPEPGZMB | |
| SCHEMBL23133164 | 0.87 | TASP1 (0.50) | TASP1ENPEPGZMBCASP1CASP3 | |
| SCHEMBL29729257 | 0.87 | ENPEP (0.47) | TASP1ENPEPCASP1CASP3CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4493275-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | Memorial Sloan Kettering Cancer Center (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024233683-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | ALUME BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| EP-4041311-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | Alume Biosciences, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-4037714-A1 | METHODS AND COMPOSITIONS FOR MODULATING MACROPHAGES POLARIZATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022120177-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11299515-B2 | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-12 | — | — | US | disclosed |
| US-11246940-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-07-06 | — | — | US | disclosed |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-05-18 | — | — | US | disclosed |
| US-10976306-B2 | Protein degradation inducing tag and usage thereof | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-04-13 | — | — | US | disclosed |
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20180164289-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10976306-B2 | Protein degradation inducing tag and usage thereof | SENP8, SENP6, SENP7 | TASP1 1024/4885ENPEP 318/4885GZMB 2908/4885 |
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TP53, TP53BP1, MDM2 | TASP1 1006/4885ENPEP 566/4885GZMB 1427/4885 |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885ENPEP 1297/4885GZMB 426/4885 |
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | KRAS, G3BP1, NRAS | TASP1 960/4885ENPEP 864/4885GZMB 2737/4885 |
| US-20180164289-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | SENP8, SENP6, SENP7 | TASP1 1024/4885ENPEP 318/4885GZMB 2908/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | TASP1 4280/4885ENPEP 60/4885GZMB 2119/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885ENPEP 1297/4885GZMB 426/4885 |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | TASP1 2942/4885ENPEP 389/4885GZMB 2116/4885 |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TP53, TP53BP1, MDM2 | TASP1 1006/4885ENPEP 566/4885GZMB 1427/4885 |
| US-20250017979-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IN VIVO SURVIVAL OF MIDBRAIN DOPAMINE NEURONS | CHAT, PINK1, DBH | TASP1 1329/4885ENPEP 3281/4885GZMB 1132/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885ENPEP 1297/4885GZMB 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.